|
邸涛.替奈普酶联合替罗非班可有效改善急性ST段抬高型心肌梗死患者心功能及预后[J].内科急危重症杂志,2025,31(6):531-535
|
| DOI：10.11768/nkjwzzzz20250609 |
| 中文关键词: 替奈普酶 替罗非班 急性ST段抬高型心肌梗死 血管阻力 α颗粒膜蛋白 |
| 英文关键词: |
| 基金项目:石家庄市科学技术研究与发展计划项目（231460473） |
|
| 摘要点击次数: 6 |
| 全文下载次数: 10 |
| 中文摘要: |
| 摘要 目的：探究替奈普酶（TNK）联合替罗非班对急性ST段抬高型心肌梗死（STEMI）患者血管阻力(SVR)及血清α颗粒膜蛋白（GMP-140）水平的影响。方法：选取行经皮冠状动脉介入治疗（PCI）的急性STEMI患者120例作为研究对象，按随机数字表法分为TNK组和联用组，各60例。其中TNK组采用TNK静脉推注，联用组在TNK组的基础上加用替罗非班。比较2组患者临床疗效、术后心肌梗死溶栓试验（TIMI）血流分级、心功能指标、GMP-140水平、主要不良心血管事件（MACEs）的发生率及不良反应发生情况。结果：联用组总有效率、TIMI血流分级优于TNK组，联用组MACEs总发生率低于TNK组（P均＜0.05）；治疗后，2组左心室射血分数（LVEF）指标升高，左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、SVR、GMP-140水平下降，且联用组较TNK组变化更显著（P均＜0.05）；TNK组、联用组不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论：TNK联合替罗非班对急性STEMI患者有较好的临床疗效，有利于心肌血流再灌注，改善心功能，减少血小板活化，阻止血栓形成，减少MACEs的发生。 |
| 英文摘要: |
| Abstract Objective: To explore the effects of teneplase (TNK) combined with tirofiban on vascular resistance and serum alpha-granule membrane protein (GMP-140) level in patients with ST-segment elevation myocardial infarction (STEMI). Methods: A total of 120 patients with STEMI who underwent percutaneous coronary intervention (PCI) in our hospital were selected as the research subjects. They were randomly divided into two groups using a random number table: the TNK group (60 cases) and the combination group (60 cases). The TNK group and the combination group were given TNK, while the combination group was given additional tirofiban. The clinical efficacy, postoperative thrombolysis in myocardial infarction (TIMI) blood flow grading, cardiac function indicators, GMP-140 level, major adverse cardiovascular events (MACEs), and adverse reactions were compared between the two groups. Results: The total effective rate and TIMI blood flow grade of the combination group were better than those of TNK group, and the total incidence of MACEs in the combination group was lower than that in the TNK group (all P< 0.05). After treatment, left ventricular ejection fraction (LVEF) increased, left ventricular end-systolic dimension (LVESD), left ventricular end-diastolic dimension (LVEDD), SVR and GMP-140 decreased in both groups, and the changes in the TNK group were more significant than those in the TNK group (P< 0.05). There was no significant difference between the TNK group and the TNK group in the total incidence of adverse reactions (P> 0.05). Conclusion: TNK combined with tirofiban has a good clinical effect on patients with STEMI, which is beneficial for myocardial blood flow reperfusion, improves the heart function, reduces platelet activation, prevents thrombosis, and reduces MACEs. |
|
|
|
|
